- <![CDATA[OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?]]><![CDATA[Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.]]>onclive · 2mo ago↗ source
- <![CDATA[Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC]]><![CDATA[Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.]]>onclive · 2mo ago↗ source
- Biopharma M&A maintains strength even as large deals waneBiopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable missing piece: meg…